Khiron Imports First Product To UK, Receives First European Prescriptions

Khiron Life Sciences (TSXV: KHRN) has officially entered the United Kingdom’s medical cannabis market, announcing this morning the receipt of its first prescriptions for patients within the country. The prescriptions are via Project Twenty21, Europe’s first and largest medical cannabis registry study.

Project Twenty21 is working towards becoming the largest body of evidence for the effectiveness and tolerability of medical cannabis, with a target of enrolling 20,000 patients by the end of 2021. The ultimate goal of which, is to demonstrate to policymakers that medical cannabis should be as widely available and affordable as other medicines. Khiron is the exclusive Latin American supplier for the project, with Khiron branded products now available to participating UK doctors.

The first import of EU GMP medical cannabis products has now been completed, and the first prescriptions under the supply agreement now received. The company has also secured a strategic partnership with a fully certified fulfillment partner whom can provide home delivery to patients for Khiron’s medical cannabis products.

“The receipt of our first prescriptions in the UK is a testament to Khiron's regulatory strengths and globally diversified supply chain strategy. We have the flexibility to source medical cannabis products from multiple countries, with an aim to optimize for quality, speed and economics. The implementation of virtual consultations in the UK and mail order fulfilment are also huge milestones, which remove friction for patients and help to drive positive health outcomes.”
Tejinder Virk, President Khiron Europe

The medical cannabis market within the United Kingdom is expected to be worth nearly one billion Euro’s by 2024, with an estimated 340,000 active patients as per a study conducted by Prohibition Partners. The market has been showing significant developments for patients, with medical cannabis clinics and doctors recently receiving approval to conduct teleconsultations with patients, further opening patient access to medical cannabis.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

Khiron Life Sciences last traded at $0.82 on the TSX Venture.


FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Drug Trade: The Three Basic Cannabis Health Company Archetypes

The popular belief that cannabis will work its way further into mainstream culture and further...

Saturday, December 21, 2019, 08:00:00 AM

Khiron Receives Authorization For Sale Of High-THC Medical Cannabis

Khiron Life Sciences (TSXV: KHRN) announced this morning that it has received authorization from the...

Wednesday, May 20, 2020, 08:47:31 AM

Harvest Moon: Khiron Life Sciences Posts Encouraging Earnings

Overall, we view the recent announcements and earnings surrounding Khiron Life Sciences (TSXV: KHRN) as...

Tuesday, May 5, 2020, 08:50:19 AM

Khiron Life “Renews” Buyback Program, Last Program Was A Bust

Khiron Life Sciences (TSXV: KHRN) this morning announced that it is renewing its normal course...

Tuesday, September 14, 2021, 08:19:09 AM

The Deep Dive Spotlight Series: Chris Naprawa of Khiron Life Sciences

The Deep Dive is stepping up our programming. We’re upgrading our Canadian small cap coverage...

Saturday, June 6, 2020, 09:00:00 AM